<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18262">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01839110</url>
  </required_header>
  <id_info>
    <org_study_id>817785</org_study_id>
    <nct_id>NCT01839110</nct_id>
  </id_info>
  <brief_title>Targeting the Right Ventricle in Pulmonary Hypertension</brief_title>
  <official_title>A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Assess the Effect of Ranolazine on Outcomes in Subjects With Pulmonary Hypertension and Right Ventricular Dysfunction Accompanied by a Comparative Study of Cellular Metabolism in Subjects With Pulmonary Hypertension With and Without Right Ventricular Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Cardiovascular Medical Research and Education Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is looking to see if giving ranolazine to subjects on stable pulmonary
      hypertension specific therapies but with right ventricular dysfunction (RVEF &lt;=40%) would
      improve their outcome. This study is accompanied by a baseline comparison of the metabolic
      profiling/microRNA/iPS cells of subjects with and without right ventricular dysfunction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number and percentage of subjects with high risk profile at end of the study</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number and percentage of subjects with high risk profile at Week 26. Patients with high risk profile are defined as patients with clinical worsening events or lack of clinical improvement at the end of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose and lipid metabolites</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure differences in glucose and lipid metabolism in subjects with and without RV dysfunction at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in glucose and lipid metabolism</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure fold changes in glucose and lipid metabolism in subjects with persistent right ventricle dysfunction after treatment with and without ranolazine.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Ranolazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ranolazine at 500mg by mouth twice per day and after two weeks will increase to 1000mg by mouth twice per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo by mouth twice per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with pulmonary hypertension who have near normal RV function (RVEF &gt;40%) will undergo same procedures in the observational arm but will not receive an intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>Ranolazine at 500mg by mouth twice per day and after two weeks will increase to 1000mg by mouth twice per day and continue for a total of 26 weeks.</description>
    <arm_group_label>Ranolazine</arm_group_label>
    <other_name>Ranexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo by mouth twice per day for a total of 26 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic pulmonary hypertension based on one of the following criteria: Idiopathic
             pulmonary arterial hypertension, Familial pulmonary arterial hypertension, pulmonary
             hypertension associated with connective tissue disease, chronic thromboembolic
             pulmonary hypertension-nonsurgical/distal vessel disease, simple congenital such as
             repaired  atrial or ventricular septal defect or unrepaired small  atrial or
             ventricular septal defect with persistent and out of proportion pulmonary arterial
             hypertension

          -  WHO functional class II, III, or IV

          -  Mean pulmonary artery pressure &gt;25 mmHg at rest

          -  Pulmonary capillary wedge pressure or left ventricular end diastolic pressure &lt; 15
             mmHg

          -  Baseline 6-minute walk test distance &gt; 50 meters

          -  Stable on baseline existing PH specific therapy for 12 weeks with no dosage change
             within 28 days prior to screening.

        Exclusion Criteria:

          -  Previous treatment with or prior sensitivity to ranolazine

          -  Any family history of corrected QT interval prolongation, congenital long QT
             syndrome, or receiving drugs that prolong the corrected QT interval

          -  Parenchymal lung disease showing total lung capacity &lt; 50% of predicted OR forced
             expiratory volume at one second/forced vital capacity &lt; 50%

          -  Portal hypertension associated with liver disease

          -  Untreated severe obstructive sleep apnea

          -  Left sided heart disease including any of the following: moderate or greater aortic
             or mitral valve disease, Any left ventricle cardiomyopathy, Left ventricular systolic
             dysfunction defined as an ejection fraction &lt; 50%, Symptomatic coronary artery
             disease

          -  Uncontrolled hypertension

          -  Uncontrolled diabetes

          -  Moderate to severe chronic renal disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuchi Han, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuchi Han, MD</last_name>
    <phone>215-662-2855</phone>
    <email>yuchi.han@uphs.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amanda Baer, MB, MBA</last_name>
    <phone>215-746-3423</phone>
    <email>baer2@mail.med.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myung Park, MD</last_name>
      <email>mpark@medicine.umaryland.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lioubov Poliakova</last_name>
      <email>lpoliako@medicine.umaryland.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Myung Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Waxman, MD, PhD</last_name>
      <email>abwaxman@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Laurie Lawler, RN</last_name>
      <email>llawler@partners.org</email>
    </contact_backup>
    <investigator>
      <last_name>Aaron Waxman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuchi Han, MD</last_name>
      <email>yuchi.han@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amanda Baer, MB, MBA</last_name>
      <email>baer2@mail.med.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Yuchi Han, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 20, 2014</lastchanged_date>
  <firstreceived_date>April 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Yuchi Han</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>pulmonary hypertension</keyword>
  <keyword>right ventricular function</keyword>
  <keyword>ranolazine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Ventricular Dysfunction, Right</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
